Last checked at 28 Oct 2013 07:00
28 October 2013
ECO Animal Health Group plc
(“ECO” or “the Company”)
(AIM:EAH)
ECO RECEIVES POSITIVE OPINION ON AIVLOSIN® FOR TURKEYS IN EUROPE
ECO is pleased to announce that it has received a positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA) for the use of Aivlosin® 625 mg/g water soluble granules in turkeys. This positive opinion will allow for the medication of drinking water with Aivlosin® for the treatment of respiratory disease associated with Ornithobacteriumrhinotracheale (ORT) in turkeys.
Aivlosin® is the first antibiotic to be granted approval in Europe for this specific indication, an economically important respiratory disease. Europe has a 30 per cent share of global turkey meat production.
Aivlosin®, ECO’s patented macrolide antibiotic, is used for the treatment of a variety of economically important respiratory and enteric (gut) diseases in pigs and poultry.
Peter Lawrence, Chairman, commented “This positive opinion from the EMA is a further encouraging step in the development of Aivlosin® as a truly global, multi-species, versatile brand that treats a multitude of different diseases. It underlines ECO’s commitment to be a major force in the global market for animal health products.”
Contacts:
| ECO Animal Health Group plc | ||
| Peter Lawrence | 020 8336 6190 | |
| Spiro Financial | 020 8336 6196 | |
| Cenkos Securities plc (Nominated Adviser) | ||
| Stephen Keys | 020 7397 8926 |
ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for the global markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.
Eco Animal Health Group Plc
Source: Eco Animal Health Group Plc
Copyright Business Wire 2013